Figure 5

Knockdown of clusterin sensitizes pancreatic cancer cells to gemcitabine via pERK1/2 inactivation. A, MIAPaCa-2 cells were treated with 1200 nM OGX-011 for 24 hours, after which proteins were prepared and subjected to Western blot as described above to monitor pERK1/2 expression. B, BxPC-3 and MIAPaCa-2 cells were treated with 1200 nM OGX-011 for 8 hours, then a wt-pERK-expressing plasmid was transfected into these cells for 24 hours, after which the cells were treated with 1.0 uM gemcitabine for 24 hours. Gemcitabine -induced cell death was determined by FACS. Representative results are shown; two additional studies yielded equivalent results (^*P < 0.05).